Item 7.01 Regulation FD Disclosure

On January 18, 2023, Monopar Therapeutics Inc. issued a press release announcing the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS).

The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference

© Edgar Online, source Glimpses